uu.seUppsala University Publications
Change search
Link to record
Permanent link

Direct link
BETA
Hallberg, Pär
Alternative names
Publications (10 of 48) Show all publications
Lindh, M., Hallberg, P., Yue, Q.-Y. & Wadelius, M. (2018). Clinical factors predicting drug-induced liver injury due to flucloxacillin. Drug, Healthcare and Patient Safety, 10, 95-101
Open this publication in new window or tab >>Clinical factors predicting drug-induced liver injury due to flucloxacillin
2018 (English)In: Drug, Healthcare and Patient Safety, ISSN 1179-1365, E-ISSN 1179-1365, Vol. 10, p. 95-101Article in journal (Refereed) Published
Abstract [en]

Objectives: Drug-induced liver injury (DILI) is a serious adverse reaction due to flucloxacillin. The pathogenesis is not fully understood. Female sex, age over 60 years, and a longer treatment duration have been suggested to be predisposing factors. Carriers of HLA-B*57:01 have an 80-fold increased risk, but due to the rarity of the reaction, testing of all patients is not cost-effective. We aimed to validate and detect clinical risk factors for flucloxacillin DILI.

Methods: Clinical characteristics of flucloxacillin-treated patients with (n=50) and without DILI (n=2,330) were compared in a retrospective case control study. Cases were recruited from the Swedish database of spontaneously reported adverse drug reactions. Treated controls were selected from the Swedish Twin Registry. Statistical comparisons were made using chi-squared test and logistic regression. The significance threshold was set to P<0.00357 to correct for multiple comparisons. Reliable variables were tested in a multiple regression model.

Results: DILI was associated with female sex, OR 2.79,95% CI 1.50-5.17, P=0.0011, and with a history of kidney stones, OR 5.51, 95% CI 2.21-13.72, P=0.0003. Cases were younger than controls, OR per increase in years 0.91,95% CI 0.88-0.94, P<0.0001, probably due to selection bias. No difference in treatment duration was detected, OR 1.03,95% CI 0.98-1.08, P=0.1790.

Conclusion: We established female sex as a risk factor for flucloxacillin-induced DILI, and a history of kidney stones was identified as a potential risk factor. Clinical risk factors for flucloxacillin-induced DILI could be used to indicate whom to test for HLA-B*57:01 before treatment.

Keywords
floxacillin, chemical and drug induced liver injury, drug-related side effects and adverse reactions, alanine transaminase, bilirubin
National Category
Gastroenterology and Hepatology
Identifiers
urn:nbn:se:uu:diva-371131 (URN)10.2147/DHPS.S178394 (DOI)000451111200001 ()30538582 (PubMedID)
Funder
Swedish Research Council, 2017-00641Swedish Research Council, 521-2011-2440Swedish Research Council, 521-2014-3370Swedish Heart Lung Foundation, 20120557Swedish Heart Lung Foundation, 20140291Swedish Heart Lung Foundation, 20170711
Available from: 2018-12-19 Created: 2018-12-19 Last updated: 2018-12-19Bibliographically approved
Kowalec, K., Wright, G. E. B., Drogemoller, B. I., Aminkeng, F., Bhavsar, A. P., Kingwell, E., . . . Carleton, B. C. (2018). Common variation near IRF6 is associated with IFN-beta-induced liver injury in multiple sclerosis. Nature Genetics, 50(8), 1081-+
Open this publication in new window or tab >>Common variation near IRF6 is associated with IFN-beta-induced liver injury in multiple sclerosis
Show others...
2018 (English)In: Nature Genetics, ISSN 1061-4036, E-ISSN 1546-1718, Vol. 50, no 8, p. 1081-+Article in journal (Refereed) Published
Abstract [en]

Multiple sclerosis (MS) is a disease of the central nervous system treated with disease-modifying therapies, including the biologic, interferon-β (IFN-β). Up to 60% of IFN-β-exposed MS patients develop abnormal biochemical liver test results1,2, and 1 in 50 experiences drug-induced liver injury3. Since genomic variation contributes to other forms of drug-induced liver injury4,5, we aimed to identify biomarkers of IFN-β-induced liver injury using a two-stage genome-wide association study. The rs2205986 variant, previously linked to differential expression of IRF6, surpassed genome-wide significance in the combined two-stage analysis (P= 2.3 × 10–8, odds ratio = 8.3, 95% confidence interval = 3.6–19.2). Analysis of an independent cohort of IFN-β-treated MS patients identified via electronic medical records showed that rs2205986 was also associated with increased peak levels of aspartate aminotransferase (P= 7.6 × 10–5) and alkaline phosphatase (P= 4.9 × 10-4). We show that these findings may be applicable to predicting IFN-β-induced liver injury, offering insight into its safer use.

National Category
Medical Genetics
Identifiers
urn:nbn:se:uu:diva-364491 (URN)10.1038/s41588-018-0168-y (DOI)000440423400006 ()30013178 (PubMedID)
Funder
Wellcome trust, 076113; 085475; 090355NIH (National Institute of Health), U01-DK065176 U01-DK065201 U01-DK065184 U01-DK065211; U01DK065193; U01-DK065238; U01-DK083023; U01-DK083027 ;U01-DK082992; U01-DK083020; U01-DK100928NIH (National Institute of Health), ULTR000445
Available from: 2018-10-29 Created: 2018-10-29 Last updated: 2018-10-29Bibliographically approved
Kharazmi, M. & Hallberg, P. (2018). Early removal of sequestrum in patients affected by medication-related osteonecrosis of the jaw [Letter to the editor]. British Journal of Oral & Maxillofacial Surgery, 56(3), 237-238
Open this publication in new window or tab >>Early removal of sequestrum in patients affected by medication-related osteonecrosis of the jaw
2018 (English)In: British Journal of Oral & Maxillofacial Surgery, ISSN 0266-4356, E-ISSN 1532-1940, Vol. 56, no 3, p. 237-238Article in journal, Letter (Other academic) Published
National Category
Dentistry
Identifiers
urn:nbn:se:uu:diva-357034 (URN)10.1016/j.bjoms.2018.01.012 (DOI)000428810300020 ()29422306 (PubMedID)
Available from: 2018-08-10 Created: 2018-08-10 Last updated: 2018-08-10Bibliographically approved
Rönnqvist, J., Hallberg, P., Yue, Q.-Y. & Wadelius, M. (2018). Fusidic Acid: A Neglected Risk Factor for Statin-Associated Myopathy. Clinical Medicine Insights: Cardiology, 12
Open this publication in new window or tab >>Fusidic Acid: A Neglected Risk Factor for Statin-Associated Myopathy
2018 (English)In: Clinical Medicine Insights: Cardiology, ISSN 1179-5468, E-ISSN 1179-5468, Vol. 12Article in journal (Refereed) Published
Abstract [en]

Background: Statins are widely used lipid-lowering drugs used for the prevention of cardiovascular disease. Statins are known to cause myopathy, an adverse drug reaction with various clinical features rhabdomyolysis.

Objective: To describe clinical characteristics of statin-treated individuals who experienced myopathy and identify risk factors of statin-associated myopathy.

Methods: A retrospective study was conducted on cases of statin-associated myopathy reported to the Swedish Medical Products Agency. Clinical factors were compared between cases and statin-treated controls not diagnosed with myopathy. Statistical methods were univariate and multivariate logistic regression and results were presented as odds ratio (OR) with 95% confidence interval (CI). To correct for multiple comparisons, the cutoff for statistical significance was set to P < .0017.

Results: In total, 47 cases of statin-associated myopathy were compared with 3871 treated controls. Rhabdomyolysis was diagnosed in 51% of the cases. Markers for cardiovascular disease were more common in cases than controls. Statistical analysis revealed the following independent risk factors for myopathy: high statin dose (OR = 1.54, calculated using the standard deviation 19.82, 95% CI = 1.32-1.80, P < .0001), and concomitant treatment with fusidic acid (OR = 1002, 95% CI = 54.55-18 410, P < .0001), cyclosporine (OR = 34.10, 95% CI = 4.43-262.45, P = .0007), and gemfibrozil (OR = 12.35, 95% CI = 2.38-64.10, P = .0028).

Keywords
adverse drug reactions, cardiovascular drugs, drug-induced disorders, drug safety, dyslipidemia, hypercholesterolemia, hyperlipidemia, myopathy and statins
National Category
Neurology
Identifiers
urn:nbn:se:uu:diva-375852 (URN)10.1177/1179546818815162 (DOI)000455898100001 ()30618488 (PubMedID)
Funder
Swedish Research Council, 521-2011-2440Swedish Research Council, 521-2014-3370Swedish Heart Lung Foundation
Available from: 2019-02-01 Created: 2019-02-01 Last updated: 2019-02-01Bibliographically approved
Wadelius, M., Eriksson, N., Smedje, H., Yue, Q.-Y. -., Magnusson, P. K. & Hallberg, P. (2018). Genome‐Wide Association Study of Pandemrix‐Induced Narcolepsy in Sweden – A Possible Role for Glial Derived Neurotrophic Factor (GDNF). Paper presented at First Nordic Conference on Personalized Medicine (NORPM 2018), May 30th ‐ June 1st 2018, Nyborg, Denmark.. Basic & Clinical Pharmacology & Toxicology, 123(S1), 12-13
Open this publication in new window or tab >>Genome‐Wide Association Study of Pandemrix‐Induced Narcolepsy in Sweden – A Possible Role for Glial Derived Neurotrophic Factor (GDNF)
Show others...
2018 (English)In: Basic & Clinical Pharmacology & Toxicology, ISSN 1742-7835, E-ISSN 1742-7843, Vol. 123, no S1, p. 12-13Article in journal, Meeting abstract (Other academic) Published
National Category
Pharmacology and Toxicology
Identifiers
urn:nbn:se:uu:diva-362656 (URN)10.1111/bcpt.13020 (DOI)000434060000033 ()
Conference
First Nordic Conference on Personalized Medicine (NORPM 2018), May 30th ‐ June 1st 2018, Nyborg, Denmark.
Note

Meeting Abstract: NorPM-O5

Available from: 2018-10-16 Created: 2018-10-16 Last updated: 2018-10-16Bibliographically approved
Watkins, P. B., Nicoletti, P., Cirulli, E., Abramson, K., Andrade, R. J., Bjornsson, E., . . . Aithal, G. P. (2018). Identification of a PTPN22 Missense Variant As a General Genetic Risk Factor for Drug-Induced Liver Injury. Paper presented at Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, NOV 09-13, 2018, San Francisco, CA. Hepatology, 68, 25A-25A
Open this publication in new window or tab >>Identification of a PTPN22 Missense Variant As a General Genetic Risk Factor for Drug-Induced Liver Injury
Show others...
2018 (English)In: Hepatology, ISSN 0270-9139, E-ISSN 1527-3350, Vol. 68, p. 25A-25AArticle in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
John Wiley & Sons, 2018
National Category
Gastroenterology and Hepatology
Identifiers
urn:nbn:se:uu:diva-368373 (URN)000446020500039 ()
Conference
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, NOV 09-13, 2018, San Francisco, CA
Available from: 2018-12-06 Created: 2018-12-06 Last updated: 2018-12-06Bibliographically approved
Sundbaum, J. K., Ericsson, N., Hallberg, P., Lehto, N., Wadelius, M. & Baecklund, E. (2018). Methotrexate treatment in rheumatoid arthritis and elevated liver enzymes: a long-term follow-up of occurrence, predictors, surveillance, and outcome in clinical practice. Paper presented at Congress of the European-League-Against-Rheumatism (EULAR), JUN 13-16, 2018, Amsterdam, NETHERLANDS. Annals of the Rheumatic Diseases, 77, 977-977
Open this publication in new window or tab >>Methotrexate treatment in rheumatoid arthritis and elevated liver enzymes: a long-term follow-up of occurrence, predictors, surveillance, and outcome in clinical practice
Show others...
2018 (English)In: Annals of the Rheumatic Diseases, ISSN 0003-4967, E-ISSN 1468-2060, Vol. 77, p. 977-977Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
BMJ Publishing Group Ltd, 2018
National Category
Rheumatology and Autoimmunity
Identifiers
urn:nbn:se:uu:diva-368665 (URN)10.1136/annrheumdis-2018-eular.2778 (DOI)000444351002595 ()
Conference
Congress of the European-League-Against-Rheumatism (EULAR), JUN 13-16, 2018, Amsterdam, NETHERLANDS
Available from: 2018-12-10 Created: 2018-12-10 Last updated: 2018-12-10Bibliographically approved
Kharazmi, M. & Hallberg, P. (2018). Secondary sinus lift: viable technique for when a membrane is raised without a graft, and fails [Letter to the editor]. British Journal of Oral & Maxillofacial Surgery, 56(3), 234-235
Open this publication in new window or tab >>Secondary sinus lift: viable technique for when a membrane is raised without a graft, and fails
2018 (English)In: British Journal of Oral & Maxillofacial Surgery, ISSN 0266-4356, E-ISSN 1532-1940, Vol. 56, no 3, p. 234-235Article in journal, Letter (Other academic) Published
National Category
Dentistry
Identifiers
urn:nbn:se:uu:diva-357033 (URN)10.1016/j.bjoms.2017.12.007 (DOI)000428810300016 ()29477491 (PubMedID)
Available from: 2018-08-10 Created: 2018-08-10 Last updated: 2018-08-10Bibliographically approved
Wadelius, M., Eriksson, N., Kreutz, R., Bondon-Guitton, E., Ibañez, L., Carvajal, A., . . . Hallberg, P. (2018). Sulfasalazine-Induced Agranulocytosis Is Associated With the Human Leukocyte Antigen Locus.. Clinical Pharmacology and Therapeutics, 103(5), 843-853
Open this publication in new window or tab >>Sulfasalazine-Induced Agranulocytosis Is Associated With the Human Leukocyte Antigen Locus.
Show others...
2018 (English)In: Clinical Pharmacology and Therapeutics, ISSN 0009-9236, E-ISSN 1532-6535, Vol. 103, no 5, p. 843-853Article in journal (Refereed) Published
Abstract [en]

Agranulocytosis is a serious, although rare, adverse reaction to sulfasalazine, which is used to treat inflammatory joint and bowel disease. We performed a genome‐wide association study comprising 9,380,034 polymorphisms and 180 HLA alleles in 36 cases of sulfasalazine‐induced agranulocytosis and 5,170 population controls. Sulfasalazine‐induced agranulocytosis was significantly associated with the HLA region on chromosome 6. The top hit (rs9266634) was located close to HLA‐B, odds ratio (OR) 5.36 (95% confidence interval (CI) (2.97, 9.69) P = 2.55 × 10−8). We HLA‐sequenced a second cohort consisting of 40 cases and 142 treated controls, and confirmed significant associations with HLA‐B*08:01, OR = 2.25 (95% CI (1.02, 4.97) P = 0.0439), in particular the HLA‐B*08:01 haplotype HLA‐DQB1*02:01‐DRB1*03:01‐B*08:01‐C*07:01, OR = 3.79 (95% CI (1.63, 8.80) P = 0.0019), and with HLA‐A*31:01, OR = 4.81 (95% CI (1.52, 15.26) P = 0.0077). The number needed to test for HLA‐B*08:01 and HLA‐A*31:01 to avoid one case was estimated to be 1,500. We suggest that intensified monitoring or alternative treatment should be considered for known carriers of HLA‐B*08:01 or HLA‐A*31:01.

National Category
Clinical Laboratory Medicine
Research subject
Clinical Pharmacology
Identifiers
urn:nbn:se:uu:diva-342623 (URN)10.1002/cpt.805 (DOI)000430118300025 ()28762467 (PubMedID)
Projects
Farmakogenomik
Funder
Science for Life Laboratory - a national resource center for high-throughput molecular bioscienceSwedish Research Council, 521-2014-3370; 521-2011-2440Swedish Heart Lung Foundation, 20120557; 20140291
Available from: 2018-02-22 Created: 2018-02-22 Last updated: 2018-06-19Bibliographically approved
Siddiqui, M. K., Maroteau, C., Veluchamy, A., Tornio, A., Tavendale, R., Carr, F., . . . Palmer, C. N. A. (2017). A common missense variant of LILRB5 is associated with statin intolerance and myalgia. European Heart Journal, 38(48), 3569-U31
Open this publication in new window or tab >>A common missense variant of LILRB5 is associated with statin intolerance and myalgia
Show others...
2017 (English)In: European Heart Journal, ISSN 0195-668X, E-ISSN 1522-9645, Vol. 38, no 48, p. 3569-U31Article in journal (Refereed) Published
Abstract [en]

Aims: A genetic variant in LILRB5 (leukocyte immunoglobulin-like receptor subfamily-B) (rs12975366: T > C: Asp247Gly) has been reported to be associated with lower creatine phosphokinase (CK) and lactate dehydrogenase (LDH) levels. Both biomarkers are released from injured muscle tissue, making this variant a potential candidate for susceptibility to muscle-related symptoms. We examined the association of this variant with statin intolerance ascertained from electronic medical records in the GoDARTS study.

Methods and results: In the GoDARTS cohort, the LILRB5 Asp247 variant was associated with statin intolerance (SI) phenotypes; one defined as having raised CK and being non-adherent to therapy [odds ratio (OR) 1.81; 95% confidence interval (CI): 1.34–2.45] and the other as being intolerant to the lowest approved dose of a statin before being switched to two or more other statins (OR 1.36; 95% CI: 1.07–1.73). Those homozygous for Asp247 had increased odds of developing both definitions of intolerance. Importantly the second definition did not rely on CK elevations. These results were replicated in adjudicated cases of statin-induced myopathy in the PREDICTION-ADR consortium (OR1.48; 95% CI: 1.05–2.10) and for the development of myalgia in the JUPITER randomized clinical trial of rosuvastatin (OR1.35, 95% CI: 1.10–1.68). A meta-analysis across the studies showed a consistent association between Asp247Gly and outcomes associated with SI (OR1.34; 95% CI: 1.16–1.54).

Conclusion: This study presents a novel immunogenetic factor associated with statin intolerance, an important risk factor for cardiovascular outcomes. The results suggest that true statin-induced myalgia and non-specific myalgia are distinct, with a potential role for the immune system in their development. We identify a genetic group that is more likely to be intolerant to their statins.

Keywords
Statins, Pharmacogenetics, Immunogenetics, Precision medicine, Adverse drug reactions, Myalgia
National Category
Cardiac and Cardiovascular Systems
Identifiers
urn:nbn:se:uu:diva-339765 (URN)10.1093/eurheartj/ehx467 (DOI)000418697400011 ()29020356 (PubMedID)
Funder
EU, FP7, Seventh Framework Programme, 602108Wellcome trust, 099177/Z/12/Z; 072960; 084726AstraZenecaSwedish Research Council, 521-2011-2440; 521-2014-3370Swedish Heart Lung Foundation, 20120557; 20140291
Available from: 2018-02-02 Created: 2018-02-02 Last updated: 2018-02-02Bibliographically approved
Organisations

Search in DiVA

Show all publications